Table 7.
Estimated gametocyte carriage rates (GCR)
|
All (N = 2027) |
Thailand (N = 922) |
The Gambia (N = 681) |
Tanzania (N = 424) |
|
| GCR (%) after 7 days (95% CI) | ||||
| Overall | 54 (52–56) | 34 (31–37) | 65 (61–69) | 71 (66 – 75) |
| Gametocytaemia on enrolment | ||||
| No | 53 (50–55) | 32(28–36) | 71 (66–75) | 69 (64–75) |
| Yes | 58 (39–45) | 40 (35–45) | 77 (71–82) | 75 (66–82) |
| Treatment | ||||
| A | 33 (30–36) | 24(20–28) | 54 (48–60) | 26 (5–53) |
| C-F | 62 (58–65) | 50 (44–55) | 81 (63–91) | 73 (68–78) |
| G-H | 85 (71–88) | 86 (82–89) | 66 (45–80) | |
| GCR (%) after 14 days (95% CI) | ||||
| Overall | 41 (38–43) | 19 (16–22) | 65 (61–69) | 57 (51–63) |
| Gametocytaemia on enrolment | ||||
| No | 42 (39–45) | 18 (14–21) | 71(66–75) | 53(46–60) |
| Yes | 41(37–45) | 23 (18–28) | 58 (51–64) | 65 (54–74) |
| Treatment1 | ||||
| A | 18(15–21) | 9 (7–12) | 38 (32–45) | 13(1–42) |
| C-F | 47(43–51) | 34 (29–40) | 81 (63–91) | 60 (54–66) |
| G-H | 80 (75–84) | 83 (77–87) | 38 (18–58) | |
1 treatments groups are defined as: A: artemisisnin combination alone or with other treatments;
C-F: other monotherapies (see Table 1); G-H: SP alone or SP with chloroquine.